Solstice shares fell 6.5% despite the company raising full-year 2026 guidance. The transcript does not identify a specific cause for the selloff; the clearest potential concern is that nuclear sales faced previously communicated product loan returns, tempering otherwise positive growth commentary.
- Third-quarter net sales rose 8%, which management said was above the top end of its guidance range; electronic materials, refrigerants, and health care packaging led growth.
- Nuclear demand indicators were positive, with backlog at $2.6 billion and contracts extending through 2039, but results were affected by product loan returns.
- Data center and AI-related applications represent approximately 6% of expected 2026 revenue, with sales up more than 50% year over year.
- Solstice repurchased $100 million of shares in the quarter and intends to substantially complete the remaining $400 million authorization by the end of Q1 2027.
- The company completed its remaining legacy Honeywell transition service agreements ahead of schedule and under budget.
Community Discussion